07:00 , Oct 20, 2016 |  BC Innovations  |  Translation in Brief

Viking’s heart bypass

Viking Therapeutics Inc. (NASDAQ:VKTX) has presented data showing its preclinical thyroid hormone receptor β agonist, VK0214 , cut down pathogenic accumulation of very long chain fatty acids (VLCFAs) in a mouse model of X-linked adrenoleukodystrophy...
07:00 , Apr 21, 2014 |  BioCentury  |  Emerging Company Profile

Minoryx: Mediating rare metabolism

Minoryx Therapeutics S.L. has two complementary strategies for developing therapies to treat inherited metabolic diseases involving enzyme deficiencies: identifying small molecule chaperones that can restore mutant enzyme function, and repurposing existing drugs to treat the...
07:00 , Jul 30, 2012 |  BioCentury  |  Finance

Blue skies for bluebird

Blue skies for bluebird Deerfield Partners made a rare investment in a private company last week when the hedge fund participated in gene therapy company bluebird bio Inc. 's $60 million series D round. Deerfield...